Ecuador vs Philippines: Average cost of drugs for extensively drug-resistant tuberculosis
Ecuador
451 constant 2022 US$
in 2024
Philippines
282 constant 2022 US$
in 2024
Ecuador rank
50th
Philippines rank
52nd
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Ecuador
- Philippines
How they compare
Ecuador currently reports 451 constant 2022 US$ against 282 constant 2022 US$ in Philippines, a difference of 169 constant 2022 US$.
That makes Ecuador's figure about 1.6 times Philippines's.
The two have swapped places 2 times across 5 shared years of data; in 2017 it was Ecuador ahead.
Ecuador ranks 50th and Philippines ranks 52nd of 56 countries.
Philippines has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Ecuador | Philippines | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 6,927 constant 2022 US$ | 9,436 constant 2022 US$ | 2,509 constant 2022 US$ | Philippines |
| 2020s | 982.33 constant 2022 US$ | 1,309 constant 2022 US$ | 326.67 constant 2022 US$ | Philippines |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Ecuador or Philippines?
- Ecuador, at 451 constant 2022 US$ against 282 constant 2022 US$ in Philippines as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Ecuador and Philippines?
- 169 constant 2022 US$, with Ecuador ahead.
- How many years of comparable data are there for Ecuador and Philippines?
- 5 years are reported by both, from 2017 to 2024.
- How do Ecuador and Philippines rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Ecuador ranks 50th and Philippines ranks 52nd of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.